- Home
- CURX vs ANTX Comparison
CURX vs ANTX Comparison
Compare CURX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURX
- ANTX
- Stock Information
- Founded
- CURX 2018
- ANTX 2017
- Country
- CURX United States
- ANTX United States
- Employees
- CURX N/A
- ANTX N/A
- Industry
- CURX Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- CURX Health Care
- ANTX Health Care
- Exchange
- CURX Nasdaq
- ANTX Nasdaq
- Market Cap
- CURX 29.7M
- ANTX 34.4M
- IPO Year
- CURX 2025
- ANTX 2022
- Fundamental
- Price
- CURX $0.70
- ANTX $1.25
- Analyst Decision
- CURX
- ANTX Buy
- Analyst Count
- CURX 0
- ANTX 2
- Target Price
- CURX N/A
- ANTX $2.00
- AVG Volume (30 Days)
- CURX 2.7M
- ANTX 67.5K
- Earning Date
- CURX 09-09-2025
- ANTX 11-12-2025
- Dividend Yield
- CURX N/A
- ANTX N/A
- EPS Growth
- CURX N/A
- ANTX N/A
- EPS
- CURX N/A
- ANTX N/A
- Revenue
- CURX N/A
- ANTX N/A
- Revenue This Year
- CURX N/A
- ANTX N/A
- Revenue Next Year
- CURX N/A
- ANTX N/A
- P/E Ratio
- CURX N/A
- ANTX N/A
- Revenue Growth
- CURX N/A
- ANTX N/A
- 52 Week Low
- CURX $3.61
- ANTX $0.98
- 52 Week High
- CURX $8.60
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- CURX N/A
- ANTX 54.35
- Support Level
- CURX N/A
- ANTX $1.23
- Resistance Level
- CURX N/A
- ANTX $1.36
- Average True Range (ATR)
- CURX 0.00
- ANTX 0.07
- MACD
- CURX 0.00
- ANTX 0.01
- Stochastic Oscillator
- CURX 0.00
- ANTX 65.22
About CURX Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.